佐力药业：百令系列明年有望以价换量实现销售持续增长

Group 1 - The core viewpoint of the article is that Zhaoli Pharmaceutical expects to achieve continuous sales growth for its Bailing series through a price-volume strategy as the national Chinese medicine procurement alliance fully implements collective purchasing [1] - The company aims to develop the Bailing series into a large-scale product with a target sales volume of 1 billion yuan in the future [1]